Iterion Therapeutics

Iterion Therapeutics is pioneering a novel approach to target the historically 'undruggable' Wnt/β-catenin signaling pathway in cancer. Its lead candidate, tegavivint, works by degrading the nuclear β-catenin co-activator TBL1, offering a potentially safer and more effective mechanism than upstream inhibitors. The company is advancing tegavivint in multiple clinical trials, with a primary focus on Wnt-mutated HCC, a population with no existing targeted therapies. Iterion's strategy includes expanding into other Wnt-driven solid tumors and hematologic malignancies, representing a significant multi-billion dollar market opportunity.

Small molecule platform targeting the Wnt/β-catenin pathway via selective degradation of nuclear β-catenin by inhibiting the co-activator TBL1.

Tegavivint is positioned as the most advanced Wnt/β-catenin inhibitor in clinical development. Competition includes companies pursuing upstream Wnt inhibitors (which have toxicity challenges) and other novel approaches like β-catenin degraders. Its primary competition in the near-term is the standard of care (e.g., TKIs in HCC) which it aims to displace based on superior efficacy in biomarker-selected patients.